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Understanding the many biological extraskeletal actions of vitamin D has increased in the past decades. Indeed, vitamin D and
analogue molecules, besides the classical actions on bone metabolism, exert several beneficial effects on metabolic homeostasis,
heart-cardiovascular, brain, and muscle physiological functions, throughout the interaction with the specific vitamin D receptor
(VDR). In particular, VDR agonists powerfully control innate and adaptive immune systemwith favorable effects on human health.
VDR ligands act as immunomodulators that are potent enough to retain anti-inflammatory effects, even though the mechanism
underlying those effects is not yet fully elucidated. VDR agonists exert a significant suppression of inflammatory processes switching
the immune response from T helper 1 (Th1) to T helper 2 (Th2) dominance and counteracting the self-enhancing inflammatory
loop between immune and resident cells, especially by cytokine release impairment.Thosemolecules are able, indeed, to reduce the
release of the interferon (IFN)𝛾-induced 10 kDa protein IP-10/CXCL10, a powerful chemokine drivingTh1-mediated inflammation.
Based on their features, VDR ligands show the potentiality to be included in immunosuppressive regimens, aimed to control auto-
and alloimmuneTh1-driven overreactivity, occurring, for example, in autoimmune disease or graft rejection.
1. Introduction
The concept that vitamin D, classically categorized as a regu-
lator of calcium/phosphorous balance and bone metabolism,
is able to act on the immune system has emerged more
than 20 years ago [1, 2]. Since then, accumulating evidence
confirmed that those pharmacologic effects on the immune
system are suppressive enough to retain therapeutic poten-
tials for the management of immune-related inflammatory
diseases. Furthermore, epidemiological studies show that
circulating altered levels of vitamin D are associated with
a higher susceptibility to immune-mediated disorders and
inflammatory diseases [3].
The pleiotropic activities in immune regulation by VDR
agonists rely on their ability to interfere with matura-
tion/differentiation/activation of the majority of the immune
system cells which express VDR, such as monocytes,
macrophages, B and T lymphocytes, neutrophils, and den-
dritic cells (DCs). Vitamin D, for example, is able to suppress
cellular immune response by inhibiting the proliferation of
T cells and the maturation of DCs, the most potent antigen-
presenting cells (APCs) [4]. Hence, vitamin D can polarize
Th1 immune response, which dominates in inflammation,
toward a more regulatory Th2 phenotype, which dominates
in tolerogenicity, by specifically repressingTh1 cytokine gene
transcription in immune cells. Notably, VDR agonists are
able to inhibit cytokine expression and release also in tissue
resident cells, with a definite anti-inflammatory effect.
In particular, we have previously reported on the ability of
two less or nonhypercalcemicVDR ligands, BXL-01-0029 and
elocalcitol, to counteract in lymphocytes and different human
resident cell types the release of CXCL10 [5–7]; this is a key
chemokine triggeringTh1 inflammatorymolecular processes,
in auto- or alloimmune response, secreted by several types
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of resident cells (skeletal muscle cells, thyrocytes, cardiomy-
ocytes, tubular renal cells, and human adrenal cells) [7–12].
In the present paper we intend to offer an overview
on VDR agonists as new pharmacological tools with anti-
inflammatory properties on immune and tissue resident cells,
with particular attention to CXCL10, as a new biomolecular
target for resolution of inflammation.
2. Vitamin D
The pleiotropic hormone vitamin D, also known as vita-
min D
3
or calcitriol, is known since almost 90 years
ago to prevent rickets in children, osteomalacia in adults,
and hypocalcemic tetany [13, 14]; for long time, its func-
tion has been considered to be exerted exclusively on
calcium, phosphorus, and bone metabolism. With the
years, beside the other vitamin D functions—for exam-
ple, on metabolism, cardiovascular system, muscle and
brain functions, and cell growth/differentiation—important
effects have been documented on the immune system.
In fact, more than 25 years ago, the immunomodula-
tory role of vitamin D emerged [3] after the observa-
tion that monocytes/macrophages from patients affected by
granulomatous disease sarcoidosis constitutively synthesize
the active form of vitamin D [4]. Vitamin D is synthe-
sized through a multistep process, which begins in the
skin. The ultraviolet light (appropriate wavelength: 270–
300 nm) photocatalyzes the conversion of the precursor
7-dehydrocholesterol to previtamin D
3
or cholecalciferol,
without any significant biological activity until its conversion
to the hormonally active form, 1,25-dihydroxycholecalciferol.
This conversion occurs in two steps. Within the liver,
cholecalciferol is hydroxylated to 25-hydroxycholecalciferol
[25(OH)D
3
] by the enzyme 25-hydroxylase (CYP2R1);
within the kidney, 25-hydroxycholecalciferol serves as a
substrate for 1-alpha-hydroxylase (CYP27B1), yielding 1,25-
dihydroxycholecalciferol or calcitriol [1,25(OH)
2
D
3
], the bio-
logically active form. Each form of vitamin D is hydrophobic
and transported throughout the body by the specific vitamin
D binding proteins (DBP). Vitamin D action is limited by
catabolism—mainly by a 24-hydroxylase (CYP24A1)—which
results in 1,24,25-trihydroxyvitamin D
3
[1,24,25(OH)
3
D
3
],
a compound with substantially lower affinity for the VDR;
this compound is further metabolized to calcitroic acid
and secreted in urine. The metabolism of vitamin D is
complex and tightly regulated [15]. Rate limiting steps in the
metabolism of vitamin D are the activity of CYP2R1, induced
by low 25(OH)D
3
levels, and the activity of CYP24A1,
induced by high levels of 25(OH)D
3
, and 1,25(OH)D
3
to
avoid vitamin D toxicity. While liver and kidney are the main
sites for vitamin D synthesis and degradation, many other
tissues (colon, prostate, breast, lung, pancreas, brain, and
endothelium) can synthesize and degrade the active form of
vitamin D. Vitamin D biologic effects are exerted throughout
the interaction with VDR, which is known to be present in
over 30 human target tissues, as reported in Table 1 [16, 17].
Such a diffuse expression in several different tis-
sues, together with metabolic enzyme presence, suggests
Table 1: VDR is almost ubiquitary expressed in humans. Many of
human tissues and organs express VDR: upon ligand-receptor inter-
action genomic and nongenomic action likely occur by endocrine,
paracrine, and autocrine mechanisms.
Human organs and tissues expressing vitamin D receptor (VDR)
Adipose Pancreatic 𝛽-cell
Adrenal Parathyroid
Bone Parotid
Brain Pituitary
Breast Placenta
Cartilage Prostate
Colon Retina
Hair follicle Skin
Heart Sperm
Intestine Stomach
Kidney Testis
Liver Thymus
Lung Thyroid
Immune cells Tonsils
Muscle, smooth and skeletal Uterus
Ovary
paracrine/autocrine mechanisms of actions, in addition to
the classical endocrine effect of the hormone.
The dominant genomic pathway, by which vitamin D
mediates its biologic effects, involves the regulation of target
genes by ligand-receptor complex in the nucleus of target
cells [18]. Summarizing, upon ligand-nuclear VDR inter-
action, vitamin D forms heterodimers with the retinoid X
receptor (RXR) and its ligand (9 cis-retinoic acid); these
dimers subsequently occupy specific binding sites on DNA,
the vitamin D response elements (VDREs). In conjunction
with other transcription factors, this complex induces the
transcription of vitamin D responsive genes [19, 20]. Besides
the well-characterized nuclear VDR, a less clearly defined
cell membrane receptor, which mediates rapid nongenomic
actions, has been hypothesized [21, 22]. Rapid nongenomic
actions of vitamin D do not affect the nuclear transcriptional
activity. Even if those vitamin D rapid mechanisms are
still unclear, evidence suggests that the initiation of the
fast nongenomic signal may involve the engagement of
either a novel membrane receptor [23] or the nuclear VDR
translocation to the cell surface [24].
Vitamin D classical genomic and “new” nongenomic
actions are involved in the regulation of several critical
functions, such as immunity, angiogenesis, differentiation,
apoptosis, and cell growth. The inhibition, for example, by
VDR ligands of prostate cell growth, either growth factor
induced or neoplastic, is exerted throughout a rapid mech-
anism that blocks the phosphorylation/activation of growth
factor receptors [25, 26]. In particular, due to their antiprolif-
erative and prodifferentiation properties, known since quite
ago [27], VDR ligands control tumoral cell growth in different
models of cancer, such as prostate, breast, and colon [28–
30]. Moreover, a strong epidemiological association between
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prostate, breast, colon cancer, and vitamin D deficiency has
been documented [31].
Interestingly, vitamin D plays a pivotal role also in
immune system cell control and differentiation, with impor-
tant effects on the immune-mediated response.
3. Protolerogenic Effects of VDR Agonists
3.1. Immune System Cells. VDR ligands usually exert their
antiproliferative, prodifferentiation, and immunomodulatory
effects throughout the activation of VDR—either constitu-
tively present or induced—in the majority of the immune
cells [32, 33]. Figure 1 summarizes the effects of vitamin D
in different immune cell types. One of the first evidence for
the immunoregulatory role of vitamin D was proven by the
vitamin D-induced differentiation of monocyte precursors
into mature macrophages [34]; the VDR high expression
in monocytes has been hypothesized to be responsible for
an autocrine mechanism for cell maturation, which, in fact,
is impaired by vitamin D deficiency [35]. Monocytes from
blood mononuclear cells (PBMCs) are able to synthesize
vitamin D under inflammatory stimuli, such as interferon
(IFN)𝛾 or bacterial antigens [36, 37]; macrophage inflam-
matory response is modulated by vitamin D throughout the
regulation of the release of critical inflammatory mediators,
such as cytokines and chemotactic cytokines or chemokines.
In both monocytes and macrophages, vitamin D regulates
its own effects by controlling VDR and CYP27B1 expres-
sion and activity; signaling throughout Toll-like receptors
(TLRs) is also engaged in association with VDR expression
increase. In human monocytes treated with vitamin D, the
expression of TLR2, TLR4, and TLR9 is inhibited, and TLR9-
dependent interleukin (IL)-6 secretion is altered [38]. The
observation that vitamin D, while promoting antimicrobial
activity in myeloid cells, also inhibits TLR2 and TLR4
expressions in monocytes, suggested a feedback mechanism
to prevent inflammatory overresponses by TLR activation
at later stage of infection [39]; this downregulatory effect in
APC might be one of the key mechanisms by which vitamin
D is able to attenuate excessive Th1-driven inflammation
and avoid downstream potential autoimmunity consequence
[40]. Some stimulatory effects have been also shown on
innate immunity, such as the increase of monocyte prolifera-
tion in vitro or IL-1 and cathelicidin (a bactericidal peptide)
release by monocytes and macrophages [41, 42]; however,
vitamin D effects on the adaptive immune response are
predominantly suppressive.
In T cells, vitamin D inhibits not only proliferation but
also IL-2 and IFN𝛾 gene and protein expressions [43–46],
likely through VDR-RXR complex interaction with VDREs
in the promoter of the genes [47, 48]; it inhibits IL-17 and
IL-2 expressions in CD4+ T cells and decreases CD8+ T cell-
mediated cytotoxicity [49], with an overall effect towards
a block of Th1-mediated response. Th2-type tolerogenic
response is also promoted by a direct enhancement of IL-
4 production [4]. Although vitamin D is known to stim-
ulate the development and differentiation of regulatory T
cells (Treg) enhancing their suppressive function [50–52],
the direct effect on T cell differentiation and function is
still unknown, since na¨ıve T cells—differently from effec-
tor/memory T cells—express VDR at very low level [42].
However, it is quite clear that Treg cell differentiation is a
key event connecting vitamin D with adaptive immunity,
with potential beneficial effects for autoimmune diseases
and host-graft rejection [3, 42, 53, 54]. It is widely accepted
that those immunosuppressive functions are substantially
driven by vitamin D induction of tolerogenic DCs [54–
56]. In DCs, vitamin D inhibits differentiation and function
as well, throughout a decrease in the expression of major
histocompatibility complex (MHC) class II molecules and
CD40, CD80, and CD86 [4, 57–59] costimulatory proteins;
it decreases IL-6, IL-23, and IL-12 [60] while simultaneously
increases IL-10 production. Those events also mirror a net
decrease inTh1 cell response in favor ofTh2-mediated events.
By reducing IL-6 and IL-23 production, vitamin D likely
inhibits also Th17 cells, another T cell subset deeply engaged
in inflammatory responses; although the precise mechanism
of vitamin D on Th17 regulation is still unclear [3], it seems
that vitamin D-mediated Th1 and Th17 suppression occurs
throughout Forkhead box protein 3 (Foxp3+) Treg cells
expansion [3]. Furthermore, B cell proliferation, plasma-cell
differentiation, and immunoglobulin (IgG) secretion are also
affected byVDR ligands [1, 61], maybe throughout their effect
on APC or T cells [62]. Vitamin D is likely to play a pivotal
role in the maintenance of B cell homeostasis by regulating
autoantibody production; notably, the correction of vitamin
D deficiency might ameliorate B cell-mediated autoimmune
disorders [63]. Finally, it is likely that endogenous production
of vitaminD bymacrophage, DCs, and T cells physiologically
regulates both innate and adaptive immune responses [64–
67]. Immune cells, indeed, seem to be not simple targets of
VDR agonists but responsible for activation/inactivation of
vitamin D metabolites [68].
3.2. Organ/Tissue Resident Cells. The ability of VDR agonists
to modify the function of T cells and DCs depends not
only on VDR expression in both cell types, but also on
the presence of common targets in their signal transduction
pathways, such as the nuclear factor 𝜅B (NF-𝜅B) [69]. NF-
𝜅B is a transcription factor well known to play a pivotal role
in proinflammatory cytokine and chemokine production and
release not just by immune system cells [70] but, remarkably,
by different tissue resident cells, as previously reported [7–
10, 12]. Based on VDR agonist capacity to inhibit NF-𝜅B
activation in tissue resident cells, a strong reduction in local
release of potent chemotactic factors by organ/tissue cells
occurs; this, in turn, mirrors a reduced recruitment of Th1
cells, macrophages, and DCs to the site of inflammation.
That feature of VDR agonists is particularly relevant for
the treatment of inflammation involved in both auto- or
alloimmune response, since it counteracts the mechanisms
underlying the self-enhancing inflammatory loop between
immune and resident cells. The potential therapeutic appli-
cation of the less-hypercalcemic VDR agonist BXL-219 for
autoimmune type 1 diabetes (T1D) has been highlighted in
nonobese diabetic (NOD) mice, which retain a pathogenesis
4 Mediators of Inflammation
Monocytes/
macrophages
Vitamin D
Dendritic
cell
VDR+
Proliferation+
CYP27B1+
IL-1+
MCH class II−
Maturation/differentiation−
IL-10+
T cells B cells
VDR+
CYP24A1+
Proliferation−
Plasma-cell differentiation−
Immunoglobulins−
Cytotoxicity−
Proliferation−
Treg+
IL-10, IL-4+
Cathelicidin+
IL-12, IL-23 and IL-6−
CD40, CD80 and CD86−
IFN𝛾, IL-2 and IL-17−
Figure 1: Effects of vitamin D on different immune system cells. Vitamin D regulates several immune system cell functions. It stimulates
monocyte proliferation and differentiation towards macrophage-like cells, by self-increasing VDR, CYP27B, and IL-1 expressions; this “fast-
forward” autocrine mechanism seems to be the basis for the subsequent maturation into macrophages, which does not take place in vitamin
D deficient conditions; macrophage specific surface antigen expression is also enhanced. Vitamin D prevents T cells from proliferation,
maturation, and releasing Th1-type molecules, such as IFN𝛾, IL-2, and IL-17, whereas it promotes Treg development. Vitamin D treatment
prevents DCs from maturation and differentiation as well, by MHC class II, costimulatory factors, and interleukin downregulation. Vitamin
D-induced protolerogenicDCs seem to be the key event for suppressive effects on immune system cells. Downregulation of B cell proliferation
and maturation seems to be an indirect consequence of the suppressive effect exerted by vitamin D on T cells and APC. (+) and (−) indicate
induction or inhibition.
similar to the humandisease. In thismodel, BXL-219-induced
block of NF-𝜅Bp65 nuclear translocation is associated with
decreased CXCL10 production by pancreatic islets, even in
presence of restimulation with TLR agonists; this is reflected
in a significant decrease in Th1 cell organ infiltration [71].
Similarly, we have reported that elocalcitol or BXL-628,
a nonhypercalcemic VDR agonist, impairs NF-𝜅Bp65 and
STAT1 nuclear translocation directly in human thyrocytes in
association with a significant decrease in cytokine-induced
CXCL10 release. This effect, in addition to a decreased
Th1- and Th17-cytokine secretion by CD4+ T cells, makes
elocalcitol to be a potential pharmacological tool in the
treatment of autoimmune thyroid diseases [5].
4. CXCL10
Chemokines and their receptors are so far critical during
inflammation to become novel targets for immunointerven-
tion [72, 73].
Among chemokines, CXCL10 plays a critical role in
the initiation and maintenance of Th1-polarized response
in autoimmune diseases or in graft injury; it appears to be
directly linked to the disease pathogenesis and not related to
a generic inflammatory status [11]. CXCL10 belongs to CXC
chemokine subfamily and modulates innate and adaptive
immune responses by controlling leukocyte trafficking [11,
74]. Under proinflammatory conditions, CXCL10 is secreted
by several types of immune cells and by different resident
cell types, as well [11]. CXCL10 exerts its action by binding
the receptor CXCR3. Remarkably, local tissue secretion of
CXCL10 represents the driving force for the recruitment of
cytotoxic immune CXCR3-positive cells, such as T, natural
killer (NK), B cells, macrophages, and DCs [75–77]. In
particular, subtype A receptor activation leads to a potent
CXCL10-induced chemotaxis for Th1 cell recruitment into
inflammation sites [78], while the activation of subtype B,
selectively expressed in human microvascular endothelial
cells, is essentially involved in angiogenesis inhibition [79].
Hence, local CXCL10 production in inflammation sites
is responsible for a positive feedback loop between IFN𝛾-
producing Th1 cells and resident cells that, in turn, release
CXCL10 upon IFN𝛾 stimulation, as summarized in Figure 2
[80]. By those mechanisms a dominance of Th1-type
cytokines and inflammatory response occurs together with a
simultaneousTh2-type response downregulation.
The induction of CXCL10, important to protect against
bacteria and some viruses infections, is described to be
associated with inflammation processes engaged either in
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Figure 2: CXCL10-CXCR3 axis. CXCL10 secreted by different types of organ-resident cells under IFN𝛾 induction is a potent chemoattractant
for CXCR3-positive immune cells, in particular for activated T cells. T cell recruitment to sites of inflammation leads to an enhanced local
increase of IFN𝛾, which, in turn, stimulates CXCL10 secretion by tissue cells; thus, a self-promoting inflammatory loop is established between
resident and immune cells, making CXCL10-CXCR3 axis a therapeutic target for resolution of inflammation.
allo- or autoimmune response. Concerning the latter ones,
different autoimmune diseases, such as rheumatoid arthritis
(RA), systemic lupus erythematosus (SLE), systemic sclerosis
(SSc), multiple sclerosis (MS), autoimmune thyroid diseases,
Addison’s disease, and T1D, are associated with an enhanced
tissue expression of CXCL10, not only with increased circu-
lating levels [81–85].
CXCL10-CXCR3 axis plays a pivotal role in the patho-
genesis of graft failure and organ rejection, as well. In fact,
CXCL10 is critical in promoting and amplifying host allore-
sponses responsible for acute allograft rejection [86–91]:
CXCL10- or CXCR3-gene-deficient mice show permanent
engraftment of cardiac transplants [86, 92]. In cardiac and
small bowel models of allograft rejection, CXCL10 neutral-
ization with monoclonal antibodies prolongs the allograft
survival [86, 87]. CXCL10 intragraft expression level is
associated with human renal [79], lung [89], and cardiac
[90, 91] allograft rejections. In addition, intragraft CXCL10
expression correlates with damage degree, rejection, and even
loss of the organ [11].
Circulating levels of CXCL10 are also increased and asso-
ciated with the rejection rate in human recipients undergoing
transplantation of organs (such as kidney, heart, lung, and
liver), cardiopulmonary bypass, and allogeneic stem cell
transplantation (SCT) [11, 93]. Importantly, CXCL10 high
pretransplant serum levels may predict the risk for the
development of acute rejection and chronic allograft vascu-
lopathy (CAV) in different human organ rejection settings
[11]. In particular, pretransplant CXCL10 serum assessment
may be helpful in the prospective determination of the use
of immune suppression therapy, in both renal and heart
transplantations [11].
5. VDR Agonists and CXCL10
The protolerogenic properties of VDR agonists, as discussed
above, render them suitable candidates as immunosuppres-
sants for either autoimmune diseases or graft rejection, as
clearly summarized by Mathieu and Adorini, since quite ago
[94]. The in vivo effect of some VDR agonists on inflam-
matory mediators/processes involved in different diseases is
depicted in Table 2 [95–102].
VDR agonists, besides their ability to switch the immune
system cell balance from Th1 to Th2 dominance, are able
to counteract CXCL10 production and release by several
resident cell types [5–7]. Indeed, as previously mentioned,
VDR ligands can prevent CXCL10 release by human thy-
rocytes or murine pancreatic cells, with potential benefits
in autoimmune diabetes or thyroiditis [5, 53]. Those data
are particularly intriguing in the light of the results from
epidemiologic studies which underline an inverse correlation
observed between vitamin D level and some autoimmune
diseases, as SLE, RA, MS or SSc, in which chemokines seem
to be engaged [103]; in addition, the vitamin D intake in
early life of animal models prone to common autoimmune
disorders (RA, MS, and autoimmune prostatitis) successfully
prevents disease occurrence [4, 96, 104]; similarly, vitamin
D supplementation in early childhood seems to be able to
protect against T1D development [105]; accordingly, vitamin
D serum levels are often decreased in patients with T1D [106],
and subjects with a vitamin D deficiency are predisposed
toward developing the disease [4, 107].
It is noteworthy that VDR agonist beneficial effects
have been shown in different models of experimental organ
transplantation as well—heart [98, 108–110], kidney [111,
112], liver [113, 114], pancreatic islets [71, 115–117], skin [99],
and small bowel allografts [98]—since they delay acute and
chronic allograft rejection.The latter effect, probably themost
interesting in terms of potential clinical application, involves
also the reduction of vascular intimal thickening—for exam-
ple, due to vascular smooth muscle and endothelial cells
hyperplasia—in association with a lesser extent of immune
cell infiltration, after the treatment with VDR agonists
[118]. Remarkably, many of the immunoregulatory properties
of VDR agonists favorable in acute and chronic allograft
rejection likely rely on their capacity to inhibit CXCL10
production by organ target cells, that is, 𝛽 cells in mouse
model of pancreatic islet transplantation [54] or human
cardiomyocytes and renal tubular cells [6, 7] in heart or
kidney transplantation. Of interest, in our hands, elocalcitol
and BXL-01-0029 significantly decreased CXCL10 secretion,
without cytotoxic effects neither in resident nor immune
cells, differently from the majority of current immunosup-
pressants. Indeed, both VDR ligands left unchanged cardiac,
renal, andCD4+ T cell viability, acting specifically onCXCL10
release [6, 7]. This effect is in line with the concept that
vitamin D in vivo plays a pivotal role in immune homeostasis
maintenance without strict immunosuppressants effects [68].
This observation could be of particular relevance as VDR
agonists might serve as dose-reducing agents to add to con-
ventional immunosuppressants in organ rejection manage-
ment or autoimmune disease. Vitamin D analogues success-
fully decreased the doses of conventional immunosuppres-
sive drugs in experimental autoimmune encephalomyelitis
(EAE) model [4]; furthermore, in EAE, the addition of the
vitamin D analogue TX527, with reduced calcemic activity,
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Table 2: In vivo effect of some VDR agonists. Vitamin D analogs suppress inflammatory mediators and processes resulting in disease
prevention.
Disease Analogs Main in vivo effects Reference
Type 1 diabetes KH1060 Type I diabetes prevention without significant effects oncalcium or bone metabolism [95]
Autoimmune prostatitis BXL-628 Inhibition of the intraprostatic inflammatory response [96]
Interstitial cystitis BXL-628 Reduction of mast cell degranulation [97]
Heart and small bowel graft MC-1288 Delay/prevention of graft rejection [98]
Skin allograft KH1060, CB966 Skin allograft survival prolongation [99]
Collagen-induced arthritis (CIA) MC-1288 CIA prevention and suppression [100]
Inflammatory bowel disease TX527 Reduction in mucosal damage and crypt loss andsuppression of the infiltration of immune cells [101]
Experimental autoimmune
encephalomyelitis (EAE) TX527 EAE prevention [102]
empowered the protective effect of IFN-𝛽 and CsA regimens,
suggesting that this compound could be considered for
clinical intervention in MS [102]; it is of interest that an
association between CXCL10 and subjects affected with MS
has been previously shown [119].
In organ transplantation, additive or synergistic effects
are reported with VDR ligands and cyclosporine A (CsA),
tacrolimus (FK-506) and sirolimus [120]. The combination
of low-dose CsA with VDR agonists results in a significant
decrease of IL-2 and IL-12 expressions and increased IL-
10 in kidney allografts [112], likely by a reduction of renal
bioactive transforming growth factor (TGF)-𝛽. Furthermore,
paricalcitol, a VDR activator, combined with trandolapril,
an angiotensin-converting enzyme inhibitor, ameliorates
obstructive nephropathy in a mouse model [121]. In humans,
a retrospective study reports that vitaminD administration is
able to delay renal graft loss in patients receiving conventional
immunosuppressive drugs [122]. In isolated human tubular
renal cells, the addition of BXL-01-0029 allows to lower FK-
506 doses to reach the same inhibitory effect on cytokine-
induced CXCL10 secretion [7].
6. Remarks and Conclusions
Given the pleiotropic effects of VDR agonists, based on
their multifaceted interaction with immune and resident
cells, it seems mandatory to encourage the research on
those molecules, which, in light of their properties—due
to their features to balance immune system homeostasis
without being classical “immunosuppressants”—appear opti-
mal candidates as novel therapeutic agents for Th1-driven
inflammatory disease resolution. Large placebo-controlled,
randomized-controlled trials should be encouraged since
some discrepancies have been reported between in vivo and
in vitro effects of vitamin D and its analogues, depending on
both chemical structure (side chain configuration) and target
cells [123].Many clinical trials have been or are currently con-
ducted by several investigators to test the therapeutic applica-
tion of vitamin D or its derivatives in inflammatory processes
underlying different pathologic conditions and diseases,
that is, metabolic and/or kidney diseases (ClinicalTrial.gov,
NCT01752244 and NCT00656032), inflammatory bowel dis-
eases (Crohn’s disease or ulcerative colitis, ClinicalTrial.gov
NCT00122184 and NCT01426724), musculoskeletal diseases
(ClinicalTrial.gov NCT01417923 and NCT01400009), and
cardiovascular diseases (ClinicalTrial.gov NCT01331317). In
this scenario, it is of particular interest a clinical trial
evaluating vitamin D repletion, inflammation, and CXCL10
(ClinicalTrial.gov NCT01570309) in coronary artery disease.
Notably, VDR ligands are able to block CXCL10, that is a
potential biomarker to monitor the inflammatory status but,
more importantly for the topic of this paper, it represents
a novel therapeutic target by which; that is, it could be
feasible to fine-tune therapy for patients undergoing organ
transplantation [11].
Furthermore, another benefit associated with the addi-
tion of VDR ligands to standard immunosuppressive reg-
imens is related to their protective effects on bone loss
[124]. Indeed, immunosuppressive agents are often associated
with detrimental effects on bone. Together with bisphospho-
nates, vitamin D metabolites are the more extensively used
molecules for bone-loss treatment. At variance with the first
ones [118, 125], vitamin D analogues are indicated also in
patients with adynamic bone disease.
Finally, it is known since long time ago that vitamin
D does not significantly interfere with protective immune
response against infective pathogens [126] and displays anti-
neoplastic properties [127], both quite relevant benefits in
order to avoid opportunistic infection or tumor development,
often associated with immunosuppression.
Despite the many advantages so far summarized, the use
of VDR agonists in clinics is until now limited to calcipotriol,
a vitamin D analogue topically applied for the treatment of
psoriasis [128].
The limit in therapeutic applications of vitamin D
undoubtedly relies on the systemic toxicity associated with
long-term intake of this hormone; in fact, the supraphysio-
logical doses of vitamin D necessary to reach the low local
effective concentration (about 10−10M) are associated with
the undesirable risk of hypercalcemia [3, 129]. Therefore,
the introduction of new molecules with immunosuppres-
sive features without causing significant hypercalcemia has
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been strongly encouraged since a while [130]. Actually,
drug development efforts should keep on designing vitamin
D analogues retaining further distinct separation between
immunomodulatory and hypercalcemic potency. Thus, the
use of molecules as BXL-01-0029 or elocalcitol, with less or
none hypercalcemic activity—and, therefore, without sys-
temic toxicity—seems suitable for inclusion in immunosup-
pressive regimens, since they own the potentiality to lower the
doses of current immunosuppressants and, thus, to reduce
the side-effects associated with immunosuppression.
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